Technology transfer is a crucial step in transitioning a biological product from development to GMP-compliant production. Successful transfer requires translating process knowledge, analytical understanding, and control strategies into a production environment. In this way, it is possible to deliver the expected quality of the medicines to the market.
Why Technology Transfer Is Critical in Biologics Development and Manufacturing?
The production of biologics depends on the interaction between the product, the production platform, and the operating environment. Technology transfer for biologics cannot be limited to simply transferring batch documentation and operating procedures (SOPs). For sponsors working with a tech transfer CDMO, the receiving organization must understand not only how the process is performed, but also why it was designed in a particular way, which parameters are critical, and how deviations can impact quality. The ICH Q10 guideline describes technology transfer as the transfer of product and process knowledge between development and production, or between production facilities.
Effective technology transfer protects healthcare anb biotech development investments by retaining knowledge generated during biological process development and analytical development. Introducing production into a GMP environment requires the integration of knowledge from the development stage with global ICH regulations.
Key Stages of Technology Transfer from Process Development to GMP Manufacturing
Each technology transfer process is specific to a given product. While it’s impossible to define a specific course, it is possible to identify the steps necessary to ensure a smooth transfer. In the case of biologics, proper partner matching is crucial.
Due diligence during the technology transfer of a biologic to a CDMO requires a systematic evaluation of facility fit and analytical readiness. A gap assessment for the technology transfer of biologics is a formal comparison between the sending site’s process and the receiving site’s capabilities to identify and mitigate risks before manufacturing begins. Among the parameters tested, process comparison is essential. Evaluation of mixing dynamics and production scale in bioreactors is particularly important from a drug substance sensitivity perspective. In the context of the analytical panel, verification of the partner’s release testing is crucial from the sponsor’s perspective. Compliance with specifications and stability results (often conducted 3 or 6 months prior to initial engineering cycles) confirms feasibility in the context of contract manufacturing.
The purpose of technology transfer is the systematic sharing of knowledge about products and processes within or between production facilities in order to achieve full product realization. The analytical methods used should take into account the equivalence of equipment, sampling procedures, scale and efficiency.
Non-GMP or engineering batches verify process fit, train teams, and expose practical gaps before GMP production begins. It’s the perfect tool for performing a final check to see if the transfer was successful. Implementing GMP takes the process to the next level in terms of quality and complexity. Systems must be qualified, and the process moves on to the manufacture of GMP-compliant biological products and, if necessary, to the validation of the process or the methods used in the analytical panel.
WHO guidelines consider technology transfer as a planned, documented, and risk-based activity throughout the product life cycle. Current guidelines cover the transfer of manufacturing processes and analytical procedures, as well as issues related to equipment, qualification, and validation.
Managing Process Knowledge, Documentation and Risk During Technology Transfer
Quality of a technology transfer depends on the quality of the knowledge being transferred. The entire operational process should be developed within the documentation framework. Batch records, development reports, deviation history analysis, analytical procedures and validation packages provide formal evidence of a successful process.
Direct interaction between subject-matter experts sometimes is essential. Quality teams can identify information not obvious from controlled documents, such as sensitivity to raw-material variability or steps requiring tight timing.
Technology transfer risk management should focus on what changes when a process moves between sites. Typical variables include scale, equipment geometry, automation, single-use components, suppliers, utilities and analytical platforms. ICH Q9(R1) supports quality risk management during technology transfer. This guideline specifically highlights its application to the design, validation and transfer of manufacturing processes, analytical methods and computerized systems. Risk assessment should evolve as new information appears, allowing the control strategy to be refined using evidence rather than assumptions.
How a Tech Transfer Partner Ensures Process Consistency and Regulatory Compliance?
EMA guidance for biotechnology-derived active substances places process development, characterisation and verification within a lifecycle framework and expects the manufacturing process to consistently perform as intended.
Capable CDMO partner supports process consistency by linking process parameters and material attributes to product quality, defining justified operating ranges and ensuring analytical methods are fit for purpose. Comparability is particularly important when process transfer introduces changes in scale, equipment or manufacturing location.
Why Technology Transfer Capabilities Matter When Choosing a CDMO in Europe?
Choosing a partner for drug development or manufacturing is a key step in scaling a business. Implementing technology transfer is crucial because moving a manufacturing process to a new location is a complex scientific and risk management exercise that determines whether a drug will remain safe, legal, and delivered on schedule.
In Europe, sponsors often compare performance, analytical capabilities, schedules, and costs. Technology transfer capabilities are equally important, as they determine how effectively an existing process can be transformed into reliable production in a new location. The most valuable partner is an organization capable of absorbing process knowledge, translating it into its production system, and retaining this knowledge throughout the product lifecycle.
An experienced European CDMO should identify gaps before they become production issues and integrate process development, analytics, quality, and GMP activities into a single program. This can reduce rework, strengthen process consistency, and improve readiness for validation, regulatory interaction, and commercial delivery.
